Cognitive alterations associated with hormone therapy in patients with breast cancer: A systematic review
- Irina Denisa Toader Autonomous University of Madrid https://orcid.org/0009-0002-6537-0742
- Juan Antonio Cruzado Complutense University of Madrid https://orcid.org/0000-0002-8906-4814
Abstract
Objective: to determine the cognitive alterations associated with hormone therapy in breast cancer patients. Methods: the present work consists of a systematic review of international experimental studies on the effects of hormone therapy on cognitive functions in women with breast cancer, following the PRISMA statement. Strict methodological criteria were followed for its selection, including only longitudinal studies with baseline and/or control group evaluations. Results: despite the discrepancies described, the results show significant impairment in verbal memory, executive functions, verbal learning, and processing speed. Conclusions: for future research it is recommended to use stricter methodological criteria and to carry out long-term follow-ups, considering that the average time of administration of these treatments’ ranges between 5 and 10 years.
References
Sociedad Espanola de Oncologia Medica. Las cifras del cancer en Espana 2023. [Acceso el 2 enero de 2024]. Disponible en: https://seom.org/images/Las_cifras_del_Cancer_en_Espana_2023.pdf
Red Espanola de Registros de Cancer (REDECAN). Estimaciones de la incidencia del cancer en Espana, 2023. [Acceso el 2 de enero de 2024]. Disponible en: https://redecan.org/storage/documents/02d62122-9adb-4d35-b6d0-551435dbe4ae.pdf
Cifras del cancer en Espana | SEOM - Dia Mundial del Cancer 2020 [Internet]. SEOM | Dia Mundial del Cancer 2020. [citado 2 de enero de 2024]. Disponible en: https://seom.org/dmcancer/cifras-del-cancer/
Azcoitia I, Arevalo MA, De Nicola AF, Garcia-Segura LM. Neuroprotective actions of estradiol revisited. Trends Endocrinol Metab 2011; 22:467-73. http://dx.doi.org/10.1016/j.tem.2011.08.002 DOI: https://doi.org/10.1016/j.tem.2011.08.002
Buwalda B, Schagen SB. Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment? Life Sciences 2013;93:581-8. http://dx.doi.org/10.1016/j.lfs.2012.12.012 DOI: https://doi.org/10.1016/j.lfs.2012.12.012
Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women’s Health Initiative Memory Study. JAMA 2004;291:2959-68. http://dx.doi.org/10.1001/jama.291.24.2959 DOI: https://doi.org/10.1001/jama.291.24.2959
Dumas J, Hancur-Bucci C, Naylor M, Sites C, Newhouse P. Estradiol interacts with the cholinergic system to affect verbal memory in postmenopausal women: evidence for the critical period hypothesis. Horm Behav 2008;53:159-69. http://dx.doi.org/10.1016/j.yhbeh.2007.09.011 DOI: https://doi.org/10.1016/j.yhbeh.2007.09.011
Azcoitia I, Yague JG, Garcia-Segura LM. Estradiol synthesis within the human brain. Neuroscience 2011;191:139-47. http://dx.doi.org/10.1016/j.neuroscience.2011.02.012 DOI: https://doi.org/10.1016/j.neuroscience.2011.02.012
Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009;360:573-87. http://dx.doi.org/10.1056/NEJMoa0807684 DOI: https://doi.org/10.1056/NEJMoa0807684
Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Annals of Oncology. 2014;25:1871-88. http://dx.doi.org/10.1093/annonc/mdu385 DOI: https://doi.org/10.1093/annonc/mdu385
Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: Americani Society of Clinical Oncology Clinical Practice Guideline Focused Update. JCO 2014;32:2255-69. http://dx.doi.org/10.1200/JCO.2013.54.2258 DOI: https://doi.org/10.1200/JCO.2013.54.2258
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378(9793):771-84. http://dx.doi.org/10.1016/S0140-6736(11)60993-8 DOI: https://doi.org/10.1016/S0140-6736(11)60993-8
Riggs BL, Hartmann LC. Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-29. http://dx.doi.org/10.1056/NEJMra022219 DOI: https://doi.org/10.1056/NEJMra022219
Liu JL, Tian DS, Li ZW, Qu WS, Zhan Y, Xie MJ, et al. Tamoxifen alleviates irradiation-induced brain injury by attenuating microglial inflammatory response in vitro and in vivo. Brain Res 2010;1316:101-11. http://dx.doi.org/10.1016/j.brainres.2009.12.055 DOI: https://doi.org/10.1016/j.brainres.2009.12.055
Newhouse P, Albert K, Astur R, Johnson J, Naylor M, Dumas J. Tamoxifen improves cholinergically modulated cognitive performance in postmenopausal women. Neuropsychopharmacology 2013;38:2632-43. http://dx.doi.org/10.1038/npp.2013.172 DOI: https://doi.org/10.1038/npp.2013.172
Newhouse P, Dumas J. Estrogen-cholinergic interactions: Implications for cognitive aging. Horm Behav 2015;74:173-85. http://dx.doi.org/10.1016/j.yhbeh.2015.06.022 DOI: https://doi.org/10.1016/j.yhbeh.2015.06.022
Lin NU, Winer EP. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 2008;26:798-805. http://dx.doi.org/10.1200/JCO.2007.15.0946 DOI: https://doi.org/10.1200/JCO.2007.15.0946
Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-29. http://dx.doi.org/10.1200/JCO.2005.09.121 DOI: https://doi.org/10.1200/JCO.2005.09.121
Chen X, Tao L, Li J, Wu J, Zhu C, Yu F, et al. The working memory and dorsolateral prefrontalhippocampal functional connectivity changes in long-term survival breast cancer patients treated with tamoxifen. Int J Neuropsychopharmacol 2017;20:374-82. http://dx.doi.org/10.1093/ijnp/pyx008 DOI: https://doi.org/10.1093/ijnp/pyx008
Sekiguchi A, Sato C, Matsudaira I, Kotozaki Y, Nouchi R, Takeuchi H, et al. Postoperative hormonal therapy prevents recovery of neurological damage after surgery in patients with breast cancer. Sci Rep 2016;6. http://dx.doi.org/10.1038/srep34671 DOI: https://doi.org/10.1038/srep34671
Ribi K, Aldridge J, Phillips KA, Thompson A, Harvey V, Thurlimann B, et al. Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. Br J Cancer 2012;106:1618-25. http://dx.doi.org/10.1038/bjc.2012.156 DOI: https://doi.org/10.1038/bjc.2012.156
Schilder CMT, Seynaeve C, Linn SC, Boogerd W, Beex LV a. M, Gundy CM, et al. Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study. Psychooncology 2012;21:479-87. http://dx.doi.org/10.1002/pon.1928 DOI: https://doi.org/10.1002/pon.1928
Phillips KA, Regan MM, Ribi K, Francis PA, Puglisi F, Bellet M, et al. Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer 2016;114:956-64. http://dx.doi.org/10.1038/bjc.2016.71 DOI: https://doi.org/10.1038/bjc.2016.71
Debess J, Riis JO, Engebjerg MC, Ewertz M. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Res Treat 2010;121:91-100. http://dx.doi.org/10.1007/s10549-010-0756-8 DOI: https://doi.org/10.1007/s10549-010-0756-8
Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009;27:3235-58. http://dx.doi.org/10.1200/JCO.2008.20.5179 DOI: https://doi.org/10.1200/JCO.2008.20.5179
Biro E, Kahan Z, Kalman J, Rusz O, Pakaski M, Irinyi T, et al. Cognitive functioning and psychological well-being in breast cancer patients on endocrine therapy. In Vivo 2019;33:1381-92. http://dx.doi.org/10.21873/invivo.11615 DOI: https://doi.org/10.21873/invivo.11615
Hermelink K, Henschel V, Untch M, Bauerfeind I, Lux MP, Munzel K. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study. Cancer 2008;113:2431-9. http://dx.doi.org/10.1002/cncr.23853 DOI: https://doi.org/10.1002/cncr.23853
Le Rhun E, Delbeuck X, Lefeuvre-Plesse C, Kramar A, Skrobala E, Pasquier F, et al. A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy. Breast Cancer Res Treat 2015;152:569-80. http://dx.doi.org/10.1007/s10549-015-3493-1 DOI: https://doi.org/10.1007/s10549-015-3493-1
Van Dyk K, Crespi CM, Bower JE, Castellon S, Petersen L, Ganz PA. The cognitive effects of endocrine therapy in breast cancer survivors: a prospective longitudinal study up to 6 years after treatment. Cancer 2019;125:681-9. http://dx.doi.org/10.1002/cncr.31858 DOI: https://doi.org/10.1002/cncr.31858
Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, Allan S, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006;94:828-34. http://dx.doi.org/10.1038/sj.bjc.6603029 DOI: https://doi.org/10.1038/sj.bjc.6603029
Hurria A, Patel SK, Mortimer J, Luu T, Somlo G, Katheria V, et al. The effect of aromatase inhibition on the cognitive function of older patients with breast cancer. Clin Breast Cancer 2014;14:132-40. http://dx.doi.org/10.1016/j.clbc.2013.10.010 DOI: https://doi.org/10.1016/j.clbc.2013.10.010
McDonald BC, Van Dyk K, Deardorff RL, Bailey JN, Zhai W, Carroll JE, et al. Multimodal MRI examination of structural and functional brain changes in older women with breast cancer in the first year of antiestrogen hormonal therapy. Breast Cancer Res Treat 2022;194:113-26. http://dx.doi.org/10.1007/s10549-022-06597-1 DOI: https://doi.org/10.1007/s10549-022-06597-1
Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: Impact of age and cognitive reserve. J Clin Oncol 2010;28:4434-40. http://dx.doi.org/10.1200/JCO.2009.27.0827 DOI: https://doi.org/10.1200/JCO.2009.27.0827
Bender CM, Merriman JD, Gentry AL, Ahrendt GM, Berga SL, Brufsky AM, et al. Patterns of change in cognitive function with anastrozole therapy. Cancer 2015;121:2627-36. http://dx.doi.org/10.1002/cncr.29393 DOI: https://doi.org/10.1002/cncr.29393
Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psychooncology 2009;18:811-21. http://dx.doi.org/10.1002/pon.1453 DOI: https://doi.org/10.1002/pon.1453
Ganz PA, Petersen L, Castellon SA, Bower JE, Silverman DHS, Cole SW, et al. Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study. J Clin Oncol 2014;32:3559-67. http://dx.doi.org/10.1200/JCO.2014.56.1662 DOI: https://doi.org/10.1200/JCO.2014.56.1662
Hedayati E, Alinaghizadeh H, Schedin A, Nyman H, Albertsson M. Effects of adjuvant treatment on cognitive function in women with early breast cancer. Eur J Oncol Nurs 2012;16:315-22. http://dx.doi.org/10.1016/j.ejon.2011.07.006 DOI: https://doi.org/10.1016/j.ejon.2011.07.006
Mandelblatt JS, Small BJ, Luta G, Hurria A, Jim H, McDonald BC, et al. Cancer-related cognitive outcomes among older breast cancer survivors in the thinking and living with cancer study. J Clin Oncol 2018;36. http://dx.doi.org/10.1200/JCO.18.00140 DOI: https://doi.org/10.1200/JCO.18.00140
Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 2010;28:1294-300. http://dx.doi.org/10.1200/JCO.2008.21.3553 DOI: https://doi.org/10.1200/JCO.2008.21.3553
Underwood EA, Jerzak KJ, Lebovic G, Rochon PA, Elser C, Pritchard KI, et al. Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study. Support Care Cancer 2019;27:3035-43. http://dx.doi.org/10.1007/s00520-018-4603-5 DOI: https://doi.org/10.1007/s00520-018-4603-5
Lee Meeuw Kjoe PR, Kieffer JM, Small BJ, Boogerd W, Schilder CM, van der Wall E, et al. Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer. JNCI Cancer Spectr 2023;7:pkad022. http://dx.doi.org/10.1093/jncics/pkad022 DOI: https://doi.org/10.1093/jncics/pkad022
Chen X, Li J, Zhang J, He X, Zhu C, Zhang L, et al. Impairment of the executive attention network in premenopausal women with hormone receptor-positive breast cancer treated with tamoxifen. Psychoneuroendocrinology 2017;75:116-23. http://dx.doi.org/10.1016/j.psyneuen.2016.10.020 DOI: https://doi.org/10.1016/j.psyneuen.2016.10.020
Chen X, Li J, Chen J, Li D, Ye R, Zhang J, et al. Decision-making impairments in breast cancer patients treated with tamoxifen. Horm Behav 2014;66:449-56. http://dx.doi.org/10.1016/j.yhbeh.2014.07.005 DOI: https://doi.org/10.1016/j.yhbeh.2014.07.005
Palmer JL, Trotter T, Joy AA, Carlson LE. Cognitive effects of Tamoxifen in pre-menopausal women with breast cancer compared to healthy controls. J Cancer Surviv 2008;2:275-82. http://dx.doi.org/10.1007/s11764-008-0070-1 DOI: https://doi.org/10.1007/s11764-008-0070-1
Schilder CM, Eggens PC, Seynaeve C, Linn SC, Boogerd W, Gundy CM, et al. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncologica 2009;48:76-85. http://dx.doi.org/10.1080/02841860802314738 DOI: https://doi.org/10.1080/02841860802314738
Bender CM, Sereika SM, Brufsky AM, Ryan CM, Vogel VG, Rastogi P, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 2007;14:995-8. http://dx.doi.org/10.1097/gme.0b013e318148b28b DOI: https://doi.org/10.1097/gme.0b013e318148b28b
Breckenridge LM, Bruns GL, Todd BL, Feuerstein M. Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors. Psychooncology 2012;21:43-53. http://dx.doi.org/10.1002/pon.1860 DOI: https://doi.org/10.1002/pon.1860
Legault C, Maki PM, Resnick SM, Coker L, Hogan P, Bevers TB, et al. Effects of Tamoxifen and Raloxifene on Memory and Other Cognitive Abilities: Cognition in the Study of Tamoxifen and Raloxifene. J Clin Oncol 2009;27:5144-52. http://dx.doi.org/10.1200/JCO.2008.21.0716 DOI: https://doi.org/10.1200/JCO.2008.21.0716
Jenkins VA, Ambroisine LM, Atkins L, Cuzick J, Howell A, Fallowfield LJ. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, doubleblind chemoprevention trial (IBIS II). Lancet Oncol 2008;9:953-61. http://dx.doi.org/10.1016/S1470-2045(08)70207-9 DOI: https://doi.org/10.1016/S1470-2045(08)70207-9
Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 2011;12:703-8. http://dx.doi.org/10.1016/S1470-2045(10)70294-1 DOI: https://doi.org/10.1016/S1470-2045(10)70294-1
Maass SWMC, Roorda C, Berendsen AJ, Verhaak PFM, de Bock GH. The prevalence of long-term symptoms of depression and anxiety after breast cancer treatment: A systematic review. Maturitas 2015;82:100-8. http://dx.doi.org/10.1016/j.maturitas.2015.04.010 DOI: https://doi.org/10.1016/j.maturitas.2015.04.010
Danhauer SC, Legault C, Bandos H, Kidwell K, Costantino J, Vaughan L, et al. Positive and negative affect, depression, and cognitive processes in the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Trial. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 2013;20:532-52. http://dx.doi.org/10.1080/13825585.2012.747671 DOI: https://doi.org/10.1080/13825585.2012.747671
Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 2010;116:3348-56. http://dx.doi.org/10.1002/cncr.25098 DOI: https://doi.org/10.1002/cncr.25098
Ahles TA, Root JC, Ryan EL. Cancer- and Cancer Treatment–Associated Cognitive Change: An Update on the State of the Science. J Clin Oncol 2012;30:3675-86. http://dx.doi.org/10.1200/JCO.2012.43.0116 DOI: https://doi.org/10.1200/JCO.2012.43.0116
Berga SL. Anastrozole: brain draining or sparing? Lancet Oncol 2008;9:913-4. http://dx.doi.org/10.1016/S1470-2045(08)70240-7 DOI: https://doi.org/10.1016/S1470-2045(08)70240-7
Format
Crossmark
License
In order to support the global exchange of knowledge, the journal Psicooncología is allowing unrestricted access to its content as from its publication in this electronic edition, and as such it is an open-access journal. The originals published in this journal are the property of the Complutense University of Madrid and any reproduction thereof in full or in part must cite the source. All content is distributed under a Creative Commons Attribution 4.0 use and distribution licence (CC BY 4.0). This circumstance must be expressly stated in these terms where necessary. You can view the summary and the complete legal text of the licence.
